On Monday, the pharmaceutical company released their latest trial result which showed their vaccine showed “robust neutralizing antibody responses.”
“Over the past nine months, hundreds of millions of people ages 12 and older from around the world have received our COVID-19 vaccine. We are eager to extend the protection afforded by the vaccine to this younger population, subject to regulatory authorization, especially as we track the spread of the Delta variant and the substantial threat it poses to children," said Pfizer CEO Albert Bourla.
The company plans to submit its results to the Food and Drug Administration (FDA) once the trials are fully complete.
Last week, the FDA rejected to approve Pfizer's COVID-19 booster shot. The agency said it needed more data.
Earlier in May, the agency authorized the Pfizer vaccine for emergency use for children aged 12 to 15. In August, the Pfizer vaccine also became the first fully FDA-approved Covid vaccine.